Nanobiotix S.A.
NASDAQ:NBTXBiotechnology
-$0.33 today
- Market cap
- $1.37B
- Beta
- 0.59
- P/E (TTM)
- -60.2
- EPS (TTM)
- -$0.51
Volume 0.04M
Average 0.08M
NBTX EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Nanobiotix S.A.NASDAQ: NBTX
EPS (Basic) · Q4 FY2025 · quarter ended Dec 2025
EPS (Basic) remains negative
Q4 FY2025 EPS (Basic) was -€0.39, compared with -€0.98 a year earlier.
Context
- EPS (Basic) grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 2 analysts of -€0.53 (-6.8%) for the fiscal year ending Dec 2026, a slowdown from the +65.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -€0.39— QoQ
- Last fiscal yearDec 2025
- -€0.5+65.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +60.2% | — | — |
| 1 year | +65.3% | -6.8% | -72.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
EUR · from the income statement
- Latest · FY2025
- (0.50) EUR
- Year-over-year change
- +65.3%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.50) | +65.3% |
| FY2024 | 2024-12-31 | (1.44) | -33.3% |
| FY2023 | 2023-12-31 | (1.08) | +34.1% |
| FY2022 | 2022-12-31 | (1.64) | -21.5% |
| FY2021 | 2021-12-31 | (1.35) | — |
EPS (Basic) vs competitors
How NBTX compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +65.3% is the highest of 11, against a peer median of -31.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $0.5 USD | -35.2% | +212.1% | |
| FY2025 | -€0.5 EUR | +65.3% | — | |
| LTM Mar 2026 | -$0.76 USD | -1050.0% | — | |
| LTM Mar 2026 | -$0.92 USD | -29.6% | — | |
| LTM Mar 2026 | -$0.98 USD | +20.7% | — | |
| LTM Sep 2026 | -$1.07 USD | -167.0% | — | |
| LTM Mar 2026 | -$1.31 USD | -18.0% | — | |
| LTM Mar 2026 | -$2.18 USD | -33.7% | — | |
| LTM Mar 2026 | -$2.8 USD | +27.6% | — | |
| LTM Mar 2026 | -$3.35 USD | -59.5% | — | |
| LTM Mar 2026 | -$3.53 USD | +6.4% | — | |
| Peer median (excluding NBTX) | — | -31.7% | +212.1% | |
Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.65M | 4.78M | 36.21M | (7.19M) | 29.64M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 2.65M | 4.78M | 36.21M | (7.19M) | 29.64M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 30.38M | 32.64M | 38.4M | 40.54M | 23.12M |
| Selling, General & Admin | 19.43M | 17.86M | 22.05M | 20.53M | 20.22M |
| Operating Expenses | 55.23M | 51.48M | 62.99M | 61.2M | 40.46M |
| Depreciation & Amortization | 1.56M | 1.5M | 551K | 592K | 1.5M |
| EBITDA | (45.61M) | (44.22M) | (23.69M) | (67.67M) | (12.07M) |
| EBITDA Margin | -1722.9% | -925.8% | -65.4% | 941.1% | -40.7% |
| Operating Income | (52.58M) | (46.7M) | (26.78M) | (68.39M) | (10.82M) |
| Operating Margin | -1986.4% | -977.8% | -74.0% | 951.2% | -36.5% |
| Interest Income | 0 | 256K | 1.22M | 2.63M | 985K |
| Interest Expense | 699.49K | 5.84M | 7.98M | 8.09M | 10.4M |
| Other Income / Expenses | 5.58M | (10.33M) | (12.8M) | 361K | (13.14M) |
| Income Before Tax | (47M) | (57.03M) | (39.58M) | (68.03M) | (23.96M) |
| Pre-Tax Margin | -1775.5% | -1194.1% | -109.3% | 946.2% | -80.8% |
| Income Tax Expense | 5K | 10K | 120K | 101K | 3K |
| Net Income | (47M) | (57.04M) | (39.7M) | (68.13M) | (23.96M) |
| Net Margin | -1775.7% | -1194.3% | -109.6% | 947.6% | -80.8% |
| EPS (Basic) | (1.35) | (1.64) | (1.08) | (1.44) | (0.50) |
| EPS (Diluted) | (1.35) | (1.64) | (1.08) | (1.44) | (0.50) |
| Weighted Avg Shares | 34.73M | 34.85M | 36.76M | 47.27M | 47.82M |
| Weighted Avg Shares (Diluted) | 34.73M | 34.85M | 36.93M | 47.27M | 47.82M |
Nanobiotix S.A.
NASDAQ:NBTX
Intrinsic Alpha fair value
Locked
Current Price
$26.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.